blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2089051

EP2089051 - ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.10.2017
Database last updated on 28.06.2024
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Newlink Genetics
Iowa State University Research Park
2503 South Loop Drive
Building 5, Suite 5100
Ames, IA 50010 / US
[2017/16]
Former [2016/48]For all designated states
Newlink Genetics
Iowa State University Research Park
2901 South Loop Drive
Building 3, Suite 3900
Ames, IA 50010 / US
Former [2011/24]For all designated states
Newlink Genetics
Iowa State University Research Park 2901 South Loop Drive, Suite 3550
Ames, IA 50010 / US
Former [2009/34]For all designated states
Newlink Genetics
Iowa State University Research Park 2901 South Loop Drive, Suite 3550
Ames, IA 50010 / US
For all designated states
JAIPURI, Firoz
Newlink Genetics Iowa State University Research Park 2901 South Loop Drive Building 3 Suite 3900
Ames, IA 50010 / US
Inventor(s)01 / JAIPURI, Firoz
Newlink Genetics
Iowa State University Research Park
2901 South Loop Drive
Building 3, Suite 3900
Ames, IA 50010 / US
02 / MAUTINO, Mario R.
Newlink Genetics
Iowa State University Research Park
2901 South Loop Drive
Building 3, Suite 3900
Ames, IA 50010 / US
03 / VAHANIAN, Nicholas N.
Newlink Genetics
Iowa State University Research Park
2901 South Loop Drive
Building 3, Suite 3900
Ames, IA 50010 / US
04 / YOUNG, Won-Bin
Newlink Genetics
Iowa State University Research Park
2901 South Loop Drive
Building 3, Suite 3900
Ames, IA 50010 / US
05 / ROSSI, Gabriela
Newlink Genetics
Iowa State University Research Park
2901 South Loop Drive
Building 3, Suite 3900
Ames, IA 50010 / US
06 / LINK, Charles, J., Jr.
Newlink Genetics
Iowa State University Research Park
2901 South Loop Drive
Building 3, Suite 3900
Ames, IA 50010 / US
 [2016/48]
Former [2009/34]01 / JAIPURI, Firoz
Newlink Genetics Iowa State University Research Park 2901 South Loop Drive Building 3, Suite 3900
Ames, IA 50010 / US
02 / MAUTINO, Mario R.
Newlink Genetics Iowa State University Research Park 2901 South Loop Drive Building 3, Suite 3900
Ames, IA 50010 / US
03 / VAHANIAN, Nicholas N.
Newlink Genetics Iowa State University Research Park 2901 South Loop Drive Building 3, Suite 3900
Ames, IA 50010 / US
04 / YOUNG, Won-Bin
Newlink Genetics Iowa State University Research Park 2901 South Loop Drive Building 3, Suite 3900
Ames, IA 50010 / US
05 / ROSSI, Gabriela
Newlink Genetics Iowa State University Research Park 2901 South Loop Drive Building 3, Suite 3900
Ames, IA 50010 / US
06 / LINK, Charles, J., Jr.
Newlink Genetics Iowa State University Research Park 2901 South Loop Drive Building 3, Suite 3900
Ames, IA 50010 / US
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2016/48]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2009/34]Williams, Aylsa
D Young & Co 120 Holborn
London EC1N 2DY / GB
Application number, filing date07867281.325.10.2007
[2009/34]
WO2007US22604
Priority number, dateUS20060862840P25.10.2006         Original published format: US 862840 P
[2009/34]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008057235
Date:15.05.2008
Language:EN
[2008/20]
Type: A2 Application without search report 
No.:EP2089051
Date:19.08.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 15.05.2008 takes the place of the publication of the European patent application.
[2009/34]
Type: B1 Patent specification 
No.:EP2089051
Date:30.11.2016
Language:EN
[2016/48]
Search report(s)International search report - published on:US07.08.2008
(Supplementary) European search report - dispatched on:EP14.05.2012
ClassificationIPC:A61K39/00, C07K5/00, C12N15/00, A61K39/39, A61P35/00
[2012/24]
CPC:
A61K39/0011 (EP,US); C07H5/04 (US); A61K39/39 (EP,US);
A61P35/00 (EP); C07H15/00 (US); C07H15/04 (US);
A61K2039/55511 (EP,US); A61K31/70 (EP,US) (-)
Former IPC [2009/34]A61K39/00, C07K5/00, C12N15/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/48]
Former [2009/34]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:ERHÖHTE IMMUNOGENITÄT VON TUMORASSOZIIERTEN ANTIGENEN MITTELS ZUGABE VON ALPHA-GAL-EPITOPEN[2009/34]
English:ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES[2009/34]
French:AUGMENTATION DE L'IMMUNOGENICITE DES ANTIGENES ASSOCIES AUX TUMEURS PAR L'ADJONCTION D'EPITOPES GAL[2009/34]
Entry into regional phase19.05.2009National basic fee paid 
19.05.2009Search fee paid 
19.05.2009Designation fee(s) paid 
19.05.2009Examination fee paid 
Examination procedure19.05.2009Examination requested  [2009/34]
23.11.2012Amendment by applicant (claims and/or description)
12.11.2013Despatch of a communication from the examining division (Time limit: M06)
16.05.2014Reply to a communication from the examining division
04.03.2015Despatch of a communication from the examining division (Time limit: M04)
14.07.2015Reply to a communication from the examining division
21.10.2015Despatch of a communication from the examining division (Time limit: M02)
18.12.2015Reply to a communication from the examining division
11.05.2016Communication of intention to grant the patent
12.09.2016Fee for grant paid
12.09.2016Fee for publishing/printing paid
12.09.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  12.11.2013
Opposition(s)31.08.2017No opposition filed within time limit [2017/45]
Fees paidRenewal fee
13.10.2009Renewal fee patent year 03
25.10.2010Renewal fee patent year 04
20.10.2011Renewal fee patent year 05
23.10.2012Renewal fee patent year 06
24.10.2013Renewal fee patent year 07
23.10.2014Renewal fee patent year 08
26.10.2015Renewal fee patent year 09
21.10.2016Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU25.10.2007
AT30.11.2016
BE30.11.2016
CY30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
MC30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SI30.11.2016
SK30.11.2016
TR30.11.2016
BG28.02.2017
GR01.03.2017
IS30.03.2017
PT30.03.2017
[2020/33]
Former [2020/15]HU25.10.2007
AT30.11.2016
BE30.11.2016
CY30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
MC30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SI30.11.2016
SK30.11.2016
TR30.11.2016
BG28.02.2017
GR01.03.2017
PT30.03.2017
Former [2019/46]HU25.10.2007
AT30.11.2016
BE30.11.2016
CY30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
MC30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SI30.11.2016
SK30.11.2016
BG28.02.2017
GR01.03.2017
PT30.03.2017
Former [2019/31]HU25.10.2007
AT30.11.2016
BE30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
MC30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SI30.11.2016
SK30.11.2016
BG28.02.2017
GR01.03.2017
PT30.03.2017
Former [2018/29]AT30.11.2016
BE30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
MC30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SI30.11.2016
SK30.11.2016
BG28.02.2017
GR01.03.2017
PT30.03.2017
Former [2017/52]AT30.11.2016
BE30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SI30.11.2016
SK30.11.2016
BG28.02.2017
GR01.03.2017
PT30.03.2017
Former [2017/38]AT30.11.2016
BE30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SK30.11.2016
BG28.02.2017
GR01.03.2017
PT30.03.2017
Former [2017/37]AT30.11.2016
BE30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
IT30.11.2016
LT30.11.2016
LV30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SK30.11.2016
GR01.03.2017
PT30.03.2017
Former [2017/36]AT30.11.2016
BE30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
LT30.11.2016
LV30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
SK30.11.2016
GR01.03.2017
PT30.03.2017
Former [2017/35]AT30.11.2016
CZ30.11.2016
DK30.11.2016
EE30.11.2016
ES30.11.2016
FI30.11.2016
LT30.11.2016
LV30.11.2016
NL30.11.2016
PL30.11.2016
RO30.11.2016
SE30.11.2016
GR01.03.2017
PT30.03.2017
Former [2017/31]AT30.11.2016
ES30.11.2016
FI30.11.2016
LT30.11.2016
LV30.11.2016
NL30.11.2016
PL30.11.2016
SE30.11.2016
GR01.03.2017
PT30.03.2017
Former [2017/26]AT30.11.2016
ES30.11.2016
FI30.11.2016
LT30.11.2016
LV30.11.2016
PL30.11.2016
SE30.11.2016
GR01.03.2017
PT30.03.2017
Former [2017/12]LV30.11.2016
Documents cited:Search[I]  - LATEMPLE D C ET AL, "Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19990715), vol. 59, no. 14, ISSN 0008-5472, pages 3417 - 3423, XP002596033 [I] 1-14 * abstract * * page 3421, column r, paragraph 3 *
 [I]  - OLIVIER MANCHES ET AL, "Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.", HAEMATOLOGICA, (20050501), vol. 90, no. 5, pages 625 - 634, XP055025927 [I] 1-14 * abstract *
 [I]  - URI GALILI, "Autologous tumor vaccines processed to express ?-gal epitopes: a practical approach to immunotherapy in cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, (20041101), vol. 53, no. 11, doi:10.1007/s00262-004-0524-x, ISSN 0340-7004, pages 935 - 945, XP055025920 [I] 1-14 * page 942, column r, paragraph l *

DOI:   http://dx.doi.org/10.1007/s00262-004-0524-x
 [I]  - ABDEL-MOTAL USSAMA ET AL, "Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Gal alpha 1-3Ga1 beta 1-4GlcNAc-R epitopes", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20060701), vol. 80, no. 14, doi:10.1128/JVI.00310-06, ISSN 0022-538X, pages 6943 - 6951, XP002543575 [I] 1-14 * abstract * * figure 1 *

DOI:   http://dx.doi.org/10.1128/JVI.00310-06
 [A]  - KANNAN P. NAICKER ET AL, "Design and synthesis of alphaGal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting", ORGANIC & BIOMOLECULAR CHEMISTRY, (20040301), vol. 2, no. 5, doi:10.1039/b313844e, ISSN 1477-0520, pages 660 - 664, XP055025921 [A] 1-14 * page 661, column r, paragraph l - page 662, column r, paragraph 1 * * figure 2 *

DOI:   http://dx.doi.org/10.1039/B313844E
 [A]  - DURRANT L G, "CANCER VACCINES", ANTI-CANCER DRUGS, LIPPINCOTT WILLIAMS & WILKINS, US; NL, (19970101), vol. 8, no. 8, doi:10.1097/00001813-199709000-00001, ISSN 0959-4973, pages 727 - 733, XP000929776 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1097/00001813-199709000-00001
 [A]  - MITCHELL M S, "CANCER VACCINES, A CRITCAL REVIEW - PART II", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, (20020101), vol. 3, no. 1, ISSN 1472-4472, pages 150 - 158, XP009009457 [A] 1-14 * the whole document *
 [A]  - CEBON J ET AL, "IMMUNOTHERAPY OF MELANOMA: TARGETING DEFINED ANTIGENS", AUSTRALASIAN JOURNAL OF DERMATOLOGY, AUSTRALIAN COLLEGE OF DERMATOLOGISTS, SYDNEY, AU, (19970601), vol. 38, no. SUPPL. 01, ISSN 0004-8380, pages S66 - S72, XP009039025 [A] 1-14 * the whole document *
International search[A]  - GALILI U. ET AL., "Intratumoral injection of alpha-gel glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines", J. IMMUNOL., (200704), vol. 178, no. 7, pages 4676 - 4687, XP008109150
 [A]  - GALILU U., "The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy", IMMUNOL. CELL BIOL., (200512), vol. 83, no. 6, pages 674 - 686, XP008085470

DOI:   http://dx.doi.org/10.1111/j.1440-1711.2005.01366.x
 [A]  - ROSSI ET AL., "Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes", CANCER RES., (200511), vol. 65, no. 22, pages 10555 - 10561, XP008109151

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-05-0627
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.